Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of A4368 in Healthy Subjects
NCT04932252Phase 1Completed
- Sponsor
- Autophagy Sciences
- Start
- Sep 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of A4368 in Nonalcoholic steatohepatitis (NASH) (8 arms), sponsored by Autophagy Sciences. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 21 days. Started Sep 2021; status: completed.
02
Drugs
A4368
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04932252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04932252.